Application of functional near-infrared spectroscopy and machine learning to predict treatment response after six months in major depressive disorder
Related Experiment Video
Updated: Jun 3, 2025

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
Published on: July 7, 2023
Cyrus Su Hui Ho1,2, Jinyuan Wang3,4, Gabrielle Wann Nii Tay5
1Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. pcmhsh@nus.edu.sg.
Abstract:
Depression treatment responses vary widely among individuals. Identifying objective biomarkers with predictive accuracy for therapeutic outcomes can enhance treatment efficiency and avoid ineffective therapies. This study investigates whether functional near-infrared spectroscopy (fNIRS) and clinical assessment information can predict treatment response in major depressive disorder (MDD) through machine-learning techniques. Seventy patients with MDD were included in this 6-month longitudinal study, with the primary treatment outcome measured by changes in the Hamilton Depression Rating Scale (HAM-D) scores. fNIRS and clinical information were strictly evaluated using nested cross-validation to predict responders and non-responders based on machine-learning models, including support vector machine, random forest, XGBoost, discriminant analysis, Naïve Bayes, and transformers. The task change of total haemoglobin (HbT), defined as the difference between pre-task and post-task average HbT concentrations, in the dorsolateral prefrontal cortex (dlPFC) is significantly correlated with treatment response (p < 0.005). Leveraging a Naïve Bayes model, inner cross-validation performance (bAcc = 70% [SD = 4], AUC = 0.77 [SD = 0.04]) and outer cross-validation results (bAcc = 73% [SD = 3], AUC = 0.77 [SD = 0.02]) were yielded for predicting response using solely fNIRS data. The bimodal model combining fNIRS and clinical data showed inferior performance in outer cross-validation (bAcc = 68%, AUC = 0.70) compared to the fNIRS-only model. Collectively, fNIRS holds potential as a scalable neuroimaging modality for predicting treatment response in MDD.

